Welcome to Last Minute Lecture.
This free chapter overview is designed to help students review and understand key concepts.
These summaries supplement not replaced the original textbook and may not be redistributed or resold.
For complete coverage, always consult the official text.
Welcome to the Deep Dive.
Today, we're jumping into something huge,
personalized medicine.
It's really a revolution in how we think about health.
We're exploring why knowing your own genetic blueprint, your DNA, is becoming absolutely essential for, well, for health care, for how drugs work for you specifically.
You know, for a long time, genetics mostly meant those rare single gene problems, think hemophilia, that was sort of the old genetics.
But the new genetics is different.
It sees that the big common diseases, Alzheimer's, heart disease, cancer, they aren't just bad luck.
They're usually a mix, right?
A result of our genes interacting with our environment, our lifestyle.
Exactly.
And that understanding, that shift, it changes everything about how we approach treatment.
So our mission today is really to unpack two key areas driving this.
First, gene therapy, the idea of actually altering the genetic instructions.
And second, pharmacogenomics, which is all about tailoring drugs based on those unique constructions you carry.
And we'll also touch on how the medical community, you know, groups like NCHPEG and ISONG are working hard to get this complex knowledge into everyday clinical practice.
It's about keeping the standards up with the science.
Okay, let's get into the science a bit.
No bio lecture needed, but we need the basics.
So we're talking about genes, right?
The fundamental units of heredity.
Think of a gene as just a segment of your DNA.
It's the specific construction needed to build a protein.
And those proteins, hormones, enzymes, you name it, they basically run your body.
The DNA has the master plan in the nucleus.
It gets transcribed into RNA, that RNA goes out and tells the ribosomes what amino acids to link up.
That's protein synthesis in a nutshell, precisely.
And the really critical point here is that tiny variations in those gene instructions can lead to huge differences in how things play out healthwise.
Like let's distinguish between genotype and phenotype.
Your genotype is the specific genetic code you have, the particular set of alleles or gene forms you inherited on your 23 pairs of chromosomes.
Right, at the raw code.
Yeah, the code.
And then your phenotype is how that code gets expressed.
It's the actual trait we can see or measure in your body, what actually shows up.
Okay, so the code versus the result.
Exactly.
And this helps us think about where diseases come from.
We still have inherited diseases passed down directly, like hemophilia being sex linked,
but much more common are acquired diseases.
These are triggered by things outside your body, like infections or environmental factors.
But genetics still plays a role there, doesn't it, through predisposition?
Absolutely.
That's the genetic predisposition.
Your genes might not guarantee you'll get, say, heart disease, but they can definitely, well, stack the deck.
They can increase your likelihood quite a bit compared to someone else.
And mapping those likelihoods, figuring out those risks.
That's really why the Human Genome Project was such a monumental effort.
Okay, let's pivot to that.
The Human Genome Project, or HGP, it was this massive international effort coordinated here by the Department of Energy and the NIH, finished back in 2003.
The goal was immense.
Identify all the estimated 30 ,000 or so genes and map out the 3 billion DNA base pairs.
It basically gave us the reference book for human genetics.
And that reference book, that map, is what made gene therapy even plausible.
Gene therapy is still largely experimental, but the idea is to use genes themselves to treat or prevent disease.
The approaches vary.
Sometimes it's about replacing a mutated gene that isn't working right with a healthy copy.
Other times, you might introduce a totally new gene to help fight off a disease.
Or you could try to switch off a mutated gene that's actively causing problems.
So you're adding or swapping genetic code.
Essentially, yes.
The aim is to transfer these exogenous genes from outside the patient's own cells to either provide a temporary fix or, ideally, make lasting changes to how the patient's genes function.
This sounds like science fiction, but you're saying it's actually happening.
It is.
A really powerful example is a drug called Luxterna.
Its generic name is quite a mouthful.
Vordagene naparvovectrizel.
Approved in 2017.
It's the first gene therapy approved for a specific inherited disease, a type of retinal dystrophy that causes blindness.
It literally works by delivering a correct copy of the faulty gene directly to the retinal cells.
It can restore vision.
Wow.
That's incredible.
But it's not routine yet.
What are the hurdles?
There are definitely challenges.
A major one is delivery.
How do you get the therapeutic gene into the cells safely and effectively?
Often, researchers use modified viruses as vectors, like little delivery trucks, to carry the gene payload.
Viruses.
That sounds risky.
Well, they're engineered to be safe, but there's always a risk.
The body's immune system might react to the viral vector itself.
They can be immunogenic.
And there's a small theoretical risk of the vector causing a viral illness.
So finding the perfect, safest delivery method is still a big focus of research.
Okay.
So direct gene therapy is powerful, but still has some kinks to work out, especially with delivery.
But there's an indirect form of gene technology that's already transformed medicine, right?
Recombinant DNA.
Absolutely.
Recombinant DNA technology, or RDNA.
This is different because you're not usually altering the patient's cells directly.
Instead, you use these techniques in the lab to make biologic drugs.
Think hormones, vaccines, those sophisticated monoclonal antibodies.
We use RDNA to produce pure, large quantities of these protein -based medicines.
Can you give a concrete example?
Insulin is the classic one.
Before RDNA, insulin for diabetics came from pigs or cows.
Not ideal.
Now, scientists take the human gene for insulin and insert it into the DNA of bacteria, often E.
coli.
These bacteria grown in huge vats become little factories churning out vast amounts of human insulin that's identical to what our own bodies make.
It revolutionized diabetes care.
The power here is just staggering.
Manipulating genes, creating biofactories.
What kind of oversight is there?
What about the ethics?
Oh, the oversight is extremely strict, as it should be.
In the U .S., the FDA has to review and approve everything before any human clinical trials can even start.
And any institution doing this research needs multiple layers of review.
There's the Institutional Review Board, IRB, focused on protecting the rights and welfare of human research subjects.
Plus, there's usually an Institutional Biosafety Committee, IBC, that specifically looks at the safety aspects of working with RDNA, making sure researchers follow strict NIH guidelines.
Okay, so safety protocols are in place, but what about the bigger picture ethical concerns?
That's a crucial conversation.
The big shadow hanging over this is the potential for eugenics.
The idea that we might start selecting desirable genetic traits before birth.
And specifically, the possibility of altering genes in human germ cells, sperm, and eggs raises fundamental questions.
Changes made there would be passed down through generations, potentially altering the human gene pool permanently.
It's a line many agree we shouldn't cross lightly, if at all.
Yeah, that's a heavy consideration.
Which brings us neatly to the next big area.
Not necessarily changing the genes, but understanding and using the information they hold.
Pharmacogenomics.
This seems like the ultimate goal of personalized medicine.
You mentioned earlier choosing and dosing drugs based specifically on your genetic makeup.
Exactly.
It's the merging of pharmacology, the study of drugs and genomics, the study of the genome.
Now, technically, there's a slight distinction people sometimes make.
Pharmacogenetics usually refers to how variations in a single gene affect drug response, whereas pharmacogenomics tends to mean looking across the whole genome for multiple genes that might influence how someone responds to a drug.
But honestly, the terms are often used interchangeably these days.
Okay.
Semantics aside, the core idea is?
The core idea is genetic polymorphisms or PMs.
These are just differences in DNA sequences, specifically alleles, that are relatively common found in at least 1 % of the population.
And these common variations can dramatically change how we handle medications.
Dramatically.
Many PMs affect the enzymes responsible for metabolizing drugs, breaking them down.
This isn't just a minor tweak.
It can completely alter a drug's effectiveness or toxicity for an individual.
So this is a major safety issue in practice.
Huge.
The best studied examples involve a family of liver enzymes called cytochrome P450 or CYP enzymes.
Based on variations in the genes for these enzymes, we can often classify people.
You might be a poor metabolizer, meaning you break down a certain drug very slowly.
Or normal metabolizer.
Or even a rapid or ultra -rapid metabolizer, breaking it down very quickly.
And knowing that makes a real difference in dosing.
A massive difference.
Let's take warfarin, the blood thinner.
It's critical but has a narrow therapeutic window.
Too little doesn't work.
Too much causes dangerous bleeding.
Well,
certain genetic variations like in the CYP2C9 gene, variants called 2 and 3, or the C1 gene, make people poor metabolizers of warfarin.
These variations in people of Asian descent.
So if they get a standard dose?
If they get a standard dose,
the drug builds up in their system because they can't clear it effectively.
Their risk of serious bleeding goes way, way up.
They need a much lower starting dose guided by their genetics.
Okay, that's a clear too much drug example.
What about the other way around?
Let's look at codeine.
It's a common painkiller, but it's actually a prodrug.
That means it needs to be converted into morphine in the body by another CYP enzyme, CYP2D6, to actually relieve pain.
Right.
So if you're a poor metabolizer for CYP2D6, you don't convert much codeine to morphine.
You'll get little or no pain relief from a standard dose.
You might get a higher dose or just a different drug altogether.
Okay.
But if you're an ultra rapid metabolizer for CYP2D6, you convert codeine to morphine super quickly.
A standard dose can suddenly flood your system with morphine, leading to potentially fatal side effects like severe sedation and respiratory depression.
This is especially dangerous in children.
Wow.
So the same dose can be ineffective for one person and toxic for another purely based on their genes.
Precisely.
And this variation isn't random across populations.
The frequencies of these different metabolizer types, poor, rapid, et cetera,
can vary significantly between different racial and ethnic groups.
Which means?
Which means cultural safety and awareness are critical here.
Assuming everyone responds the same way to a standard dose is not just inefficient, it can be dangerous.
Routine genetic testing before prescribing certain drugs is becoming more common.
And we're starting to see this on drug labels now too, right?
Specific advice based on genetic markers.
Yes, increasingly.
The FDA is mandating or recommending genetic testing for more drugs and labels often include specific genomic biomarker information telling doctors how to adjust doses based on a patient's known genetic profile.
This is clearly transforming pharmacy and medicine.
So let's bring it to the bedside.
What does all this mean for nurses who are right there with the patients?
It's a really important question.
Nurses aren't generally expected to become expert genetic counselors overnight.
That's a specialized role, but they absolutely need a solid working knowledge of these genetic principles.
Because as we've said, almost every condition they encounter will have some genetic component, even if it's just predisposition or influencing drug response.
And where does this fit into their daily work?
The nursing process?
Right at the beginning, during assessment.
It elevates the importance of taking a really thorough patient and family history.
We're talking at least three generations if possible.
Nurses need to be listening for red flags.
Things like, is there a higher rate of a certain disease compared to average?
Was someone diagnosed unusually young?
Did a family member have multiple different types of cancer?
These suggest a potential inherited predisposition.
And specifically related to the drug metabolism issues we just discussed.
Yes, that's key too.
Nurses need to specifically ask, have you or has anyone in your family ever had an unusual reaction to a medication, a drug that didn't work when it should have, or one that caused surprisingly severe side effects?
Because that could be a clue.
Exactly.
That could be a direct clue pointing towards one of those CYP enzyme variations, suggesting they might metabolize certain drugs differently.
It's a vital piece of the assessment puzzle.
Beyond assessment, what about protecting the patient?
This genetic information is incredibly personal.
Hugely important.
Nurses play a critical role in safeguarding patient rights.
First, regarding informed consent.
Before any genetic testing happens, the nurse often helps ensure the patient truly understands the test, its implications, what the results might mean, and that the formal consent process has been done correctly.
And then managing the information itself.
Absolutely.
Privacy and confidentiality are paramount.
Genetic information isn't just about the individual, it can have implications for their entire family.
And there are potential risks, like discrimination from insurers or employers, although there are laws like GINA in the U .S.
to prevent that.
So the patient controls who sees it.
The patient has the absolute right to decide who sees their genetic test results.
They can choose not to share them, even with close family members.
The nurse, along with the whole healthcare team, has a profound responsibility to protect that information from improper disclosure.
No exceptions.
It's a shared duty, then.
It really is.
Protecting patients from the misuse of their genetic information is a collective responsibility for all healthcare providers.
Professional nursing organizations are actively developing guidelines and competencies to help nurses navigate these complex ethical waters.
Okay, this has been a really insightful deep dive.
Let's recap the big picture.
Gene therapy, while still evolving, holds real promise for treating diseases by fixing or altering the underlying genetic code.
And pharmacogenomics is already here, driving us towards truly personalized drug therapy, selecting the right drug at the right person based on their unique genetics.
The goal is maximizing the good effects while minimizing the bad.
Right.
Avoiding those adverse events we talked about, like the warfarin bleeding risk or the codeine overdose risk.
It's about safety at efficacy.
So customizing treatment based on our individual blueprint.
Exactly.
And that leads us to a final thought for you, our listener, to ponder.
As this technology, genotyping for drug metabolism enzymes or disease risks, gets cheaper and more routine, you'll likely have the ability to know your personal genetic risk for various conditions, years, even decades before they might ever develop.
So the question becomes,
if you knew, with reasonable certainty, your genetic likelihood of developing, say, heart disease or specific cancer 30 years from now, how would having that knowledge today actually change how you live your life?
How would it shape your choices about diet, lifestyle, or even medical screenings?
It's a future that's coming fast.